Pfizer Inc. (NYSE:PFE) Shares Sold by Investment House LLC

Investment House LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,698 shares of the biopharmaceutical company’s stock after selling 4,075 shares during the period. Investment House LLC’s holdings in Pfizer were worth $523,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on PFE shares. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $26.18 on Thursday. The company has a market cap of $148.35 billion, a P/E ratio of 18.57, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The business’s 50-day simple moving average is $26.19 and its 200 day simple moving average is $27.08. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.